Christiane Ahlers

No ORCID on file · 5 papers in corpus · active 2015-2020

Study types

  • article 3
  • other 2

Condition tags

  • endometriosis 4
  • chronic_pelvic_pain 3
article 2020
·doi:10.1080/13625187.2020.1731734

Women aged ≤25 and >25 years have a similar experience with an E2V/DNV oral contraceptive, supporting this as an appropriate contraceptive option in younger and older women.

article 2019
·doi:10.60692/41gzg-zzt23

Dienogest has been shown to substantially improve endometriosis-associated symptoms such as debilitating chronic pelvic pain, and in turn, health-related quality of life (HRQoL). To date, there is no data on patient-reported outcomes reflec…

other 2019
BMC women's health ·doi:10.1186/s12905-019-0758-6

BACKGROUND: Dienogest has been shown to substantially improve endometriosis-associated symptoms such as debilitating chronic pelvic pain, and in turn, health-related quality of life (HRQoL). To date, there is no data on patient-reported out…

article 2019
·doi:10.60692/v9r87-9ce55

Dienogest has been shown to substantially improve endometriosis-associated symptoms such as debilitating chronic pelvic pain, and in turn, health-related quality of life (HRQoL). To date, there is no data on patient-reported outcomes reflec…

other 2015
International journal of women's health ·doi:10.2147/IJWH.S77202

BACKGROUND: In four randomized, controlled, European trials, dienogest 2 mg once daily demonstrated significant efficacy for lesion reduction and reduction in pain intensity in endometriosis. We describe a pooled analysis of the safety and …